Выпуск

The Innovation-Regulation Paradox: Building Durable Biotechnology Medicine

Deep Dive Ortho — Orthopaedic Surgery, AI & Digital Health Podcast. · 2 ноября 2026 г. · 33 мин

This episode explores the innovation-regulation paradox in biotechnology, illustrated through the contrasting case studies of the approved CRISPR therapy Casgevy and the controversial experiments of He Jiankui . While He Jiankui bypassed institutional safeguards to edit human embryos, leading to ethical violations and legal consequences, Vertex Pharmaceuticals integrated regulatory requirements directly into their scientific process to achieve the first global approval for a CRISPR-based medicine. This comparison highlights that regulation should not be viewed as a hindrance to progress but as an essential collaborator that ensures the safety, durability, and legitimacy of medical breakthroughs. The author argues that regulatory fluency is a vital scientific competency for leaders, as the technical success of a therapy is meaningless without the institutional architecture required for its delivery. Ultimately, the text transitions from the challenges of discovery to the implementation gap , noting that high costs and logistical complexity remain significant hurdles for patient access. Through the Steering Cycle framework, the sources emphasize that navigating the tension between rapid innovation and rigorous oversight is the hallmark of effective biotechnology leadership.

Страница выпуска